Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Earnings for Mirati Therapeutics, Inc. (MRTX)
Earnings in 2022 (TTM): $-740,359,000
According to Mirati Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-740,359,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Mirati Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-740,359,000 | $-740,867,000 |
| 2021 | $-578,485,000 | $-581,784,000 |
| 2020 | $-357,937,000 | $-357,426,000 |
| 2019 | $-213,256,000 | $-212,597,000 |
| 2018 | $-98,418,000 | $-98,418,000 |
| 2017 | $-70,430,000 | $-70,484,000 |
| 2016 | $-83,118,000 | $-83,143,000 |
| 2015 | $-64,544,000 | $-64,507,000 |
| 2014 | $-43,698,000 | $-43,684,000 |
| 2013 | $-52,882,000 | $-52,872,000 |
| 2012 | $-20,320,055 | $-20,359,257 |
| 2011 | $ | $-9,526,934 |
| 2010 | $-14,684,650 | $-14,688,650 |
| 2009 | $-22,400,917 | $-22,528,889 |
| 2008 | $-7,492,194 | $-7,377,979 |
| 2007 | $-22,237,706 | $-22,237,706 |
| 2006 | $-1,169,802 | $-6,444,553 |
| 2005 | $-13,165,424 | $-13,165,424 |
| 2004 | $-9,090,490 | $-9,147,197 |
| 2003 | $-4,122,285 | $-4,221,949 |